サマリー

主な調査結果
欧州の創薬市場は、予測期間である2022年から2030年にかけて、CAGR6.90%を予測する。創薬開発のための共同研究の増加、先端技術、研究開発費の増加が、同地域の市場成長に影響を及ぼしています。
市場インサイト
イタリア、ロシア、フランス、ドイツ、イギリス、スペイン、スカンジナビア、その他のヨーロッパは、ヨーロッパ創薬市場の成長評価のために分析されています。ドイツでは、製薬業界は投資の増加を目の当たりにしています。また、2019年には研究開発型の製薬会社が499件の臨床試験に資金を提供しました。同年、製薬研究開発企業は640の生物製剤を臨床開発しており、そのうちフェーズIII資産の82%は新規生物製剤であった。生物学的製剤の開発は、主に感染症、免疫学、腫瘍学に重点を置いている。
イタリアでは、AIFA（イタリア医薬品庁）が医薬品規制を所管する国家機関です。AIFAは、厚生省と経済省の指導と監視のもと、費用対効果を重視し、透明性のある自律的な運営を行っています。スペインは、新薬の臨床試験を行うのに適した国です。新薬の研究開発モデルは協力的で、国際的な展望を獲得しています。このような点が、製薬会社による国内での研究投資をもたらしています。
さらに、ハイエンドの技術的進歩、熟練した労働力、著名な製薬会社の存在により、欧州は創薬における主要市場のひとつとなっています。欧州医療機関（EMA）と欧州委員会の法律の存在も、この地域の市場展望にさらに貢献しています。
競争力のある洞察
市場に進出している主要企業には、Novartis AG、Johnson & Johnson、Merck & Co Inc、Pfizer Incなどがあります。
当社のレポート提供は以下の通りです。
- 市場全体に関する主要な知見の調査
- 市場力学（推進要因、抑制要因、機会、課題）の戦略的な内訳
- 全セグメント、サブセグメント、地域の3年分の過去データとともに、最低9年間の市場予測を掲載
- 市場細分化により、主要セグメントを徹底的に評価し、その市場推定値を提示
- 地域別分析。言及された地域および国別セグメントの評価とその市場占有率
- 主要な分析ポーターの5つの力分析、ベンダーランドスケープ、オポチュニティマトリックス、キーバイヤークライテリア、など。
- コンペティティブ・ランドスケープは、主要企業を要因や市場シェアなどに基づいて理論的に説明したものです。
- 企業プロファイリング。詳細な企業概要、提供する製品/サービス、SCOT分析、最近の戦略的展開など

ページTOPに戻る

目次

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. GROWING R&D FOR TACKLING SEVERAL DISEASES
3.1.2. TECHNOLOGICAL ADVANCEMENTS
3.2. KEY RESTRAINTS
3.2.1. EXTENSIVE TIME-CONSUMING PROCESS
3.2.2. HIGHLY REGULATED MARKET
3.2.3. PROJECT FEASIBILITY AND SUCCESS RATE
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON DRUG DISCOVERY INDUSTRY
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. DRUG DISCOVERY AND DEVELOPMENT PROCESS
4.5.1. DRUG DISCOVERY AND DEVELOPMENT
4.5.2. PRECLINICAL RESEARCH
4.5.3. CLINICAL RESEARCH
4.5.4. REGULATORY AUTHORITY REVIEW
4.5.5. POST MARKET SAFETY MONITORING
4.6. REGULATORY FRAMEWORK
5. MARKET BY DRUG TYPE
5.1. SMALL MOLECULE DRUG
5.2. BIOLOGIC DRUG
6. MARKET BY SERVICE
6.1. CHEMICAL SERVICES
6.2. DRUG METABOLISM AND PHARMACOKINETICS SERVICES
6.3. BIOLOGICAL SERVICES
6.4. OTHER PHARMACEUTICAL SERVICES
7. MARKET BY END-USER
7.1. PHARMACEUTICAL COMPANIES
7.2. CONTRACT RESEARCH ORGANIZATIONS
7.3. RESEARCH INSTITUTES
7.4. OTHER END-USERS
8. MARKET BY TECHNOLOGY
8.1. HIGH THROUGHPUT SCREENING
8.2. SPECTROSCOPY
8.3. COMBINATORIAL CHEMISTRY
8.4. BIOCHIPS
8.5. PHARMACOGENOMICS AND PHARMACOGENETICS
8.6. BIOINFORMATICS
8.7. METABOLOMICS
8.8. NANOTECHNOLOGY
8.9. OTHER TECHNOLOGIES
9. GEOGRAPHICAL ANALYSIS
9.1. EUROPE
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. KEY GROWTH ENABLERS
9.1.3. KEY CHALLENGES
9.1.4. KEY PLAYERS
9.1.5. COUNTRY ANALYSIS
9.1.5.1. UNITED KINGDOM
9.1.5.2. GERMANY
9.1.5.3. FRANCE
9.1.5.4. ITALY
9.1.5.5. RUSSIA
9.1.5.6. SPAIN
9.1.5.7. SCANDINAVIA
9.1.5.8. REST OF EUROPE
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. MERGERS & ACQUISITIONS
10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
10.1.3. PARTNERSHIPS & AGREEMENTS
10.1.4. BUSINESS EXPANSIONS & DIVESTITURES
10.2. COMPANY PROFILES
10.2.1. AGILENT TECHNOLOGIES INC
10.2.2. ASTRAZENECA PLC
10.2.3. BAYER AG
10.2.4. CHARLES RIVER LABORATORIES INTERNATIONAL INC
10.2.5. ELI LILLY AND COMPANY
10.2.6. EVOTEC SE
10.2.7. GLAXOSMITHKLINE PLC
10.2.8. ICON PLC
10.2.9. IQVIA HOLDINGS INC
10.2.10. JOHNSON & JOHNSON
10.2.11. MERCK & CO INC
10.2.12. NOVARTIS AG
10.2.13. PFIZER INC
10.2.14. ROCHE AG



LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - EUROPE DRUG DISCOVERY
TABLE 2: REGULATORY FRAMEWORK
TABLE 3: EUROPE DRUG DISCOVERY MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 4: EUROPE DRUG DISCOVERY MARKET, BY DRUG TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 5: EUROPE DRUG DISCOVERY MARKET, BY SERVICE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 6: EUROPE DRUG DISCOVERY MARKET, BY SERVICE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 7: EUROPE DRUG DISCOVERY MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 8: EUROPE DRUG DISCOVERY MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 9: EUROPE DRUG DISCOVERY MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 10: EUROPE DRUG DISCOVERY MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 11: EUROPE DRUG DISCOVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 12: EUROPE DRUG DISCOVERY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 13: LEADING PLAYERS OPERATING IN EUROPE DRUG DISCOVERY MARKET
TABLE 14: LIST OF MERGERS & ACQUISITIONS
TABLE 15: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 16: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 17: LIST OF BUSINESS EXPANSIONS & DIVESTITURES




LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER’S FIVE FORCES ANALYSIS
FIGURE 3: OPPORTUNITY MATRIX
FIGURE 4: DRUG DISCOVERY AND DEVELOPMENT PROCESS
FIGURE 5: EUROPE DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2021
FIGURE 6: EUROPE DRUG DISCOVERY MARKET, BY SMALL MOLECULE DRUG, 2022-2030 (IN $ MILLION)
FIGURE 7: EUROPE DRUG DISCOVERY MARKET, BY BIOLOGIC DRUG, 2022-2030 (IN $ MILLION)
FIGURE 8: EUROPE DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY SERVICE, IN 2021
FIGURE 9: EUROPE DRUG DISCOVERY MARKET, BY CHEMICAL SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 10: EUROPE DRUG DISCOVERY MARKET, BY DRUG METABOLISM AND PHARMACOKINETICS SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 11: EUROPE DRUG DISCOVERY MARKET, BY BIOLOGICAL SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 12: EUROPE DRUG DISCOVERY MARKET, BY OTHER PHARMACEUTICAL SERVICES, 2022-2030 (IN $ MILLION)
FIGURE 13: EUROPE DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021
FIGURE 14: EUROPE DRUG DISCOVERY MARKET, BY PHARMACEUTICAL COMPANIES, 2022-2030 (IN $ MILLION)
FIGURE 15: EUROPE DRUG DISCOVERY MARKET, BY CONTRACT RESEARCH ORGANIZATIONS, 2022-2030 (IN $ MILLION)
FIGURE 16: EUROPE DRUG DISCOVERY MARKET, BY RESEARCH INSTITUTES, 2022-2030 (IN $ MILLION)
FIGURE 17: EUROPE DRUG DISCOVERY MARKET, BY OTHER END-USERS, 2022-2030 (IN $ MILLION)
FIGURE 18: EUROPE DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021
FIGURE 19: EUROPE DRUG DISCOVERY MARKET, BY HIGH THROUGHPUT SCREENING, 2022-2030 (IN $ MILLION)
FIGURE 20: EUROPE DRUG DISCOVERY MARKET, BY SPECTROSCOPY, 2022-2030 (IN $ MILLION)
FIGURE 21: EUROPE DRUG DISCOVERY MARKET, BY COMBINATORIAL CHEMISTRY, 2022-2030 (IN $ MILLION)
FIGURE 22: EUROPE DRUG DISCOVERY MARKET, BY BIOCHIPS, 2022-2030 (IN $ MILLION)
FIGURE 23: EUROPE DRUG DISCOVERY MARKET, BY PHARMACOGENOMICS AND PHARMACOGENETICS, 2022-2030 (IN $ MILLION)
FIGURE 24: EUROPE DRUG DISCOVERY MARKET, BY BIOINFORMATICS, 2022-2030 (IN $ MILLION)
FIGURE 25: EUROPE DRUG DISCOVERY MARKET, BY METABOLOMICS, 2022-2030 (IN $ MILLION)
FIGURE 26: EUROPE DRUG DISCOVERY MARKET, BY NANOTECHNOLOGY, 2022-2030 (IN $ MILLION)
FIGURE 27: EUROPE DRUG DISCOVERY MARKET, BY OTHER TECHNOLOGIES, 2022-2030 (IN $ MILLION)
FIGURE 28: EUROPE DRUG DISCOVERY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
FIGURE 29: UNITED KINGDOM DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 30: GERMANY DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 31: FRANCE DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 32: ITALY DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 33: RUSSIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 34: SPAIN DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 35: SCANDINAVIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
FIGURE 36: REST OF EUROPE DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)